Abstract
Durante las últimas décadas, el desarrollo en tecnología de edición humana ha superado difíciles obstáculos y ha planteado
nuevos paradigmas sobre el futuro de la genética humana, gracias a su capacidad de identificar tempranamente y corregir mutaciones causantes de enfermedades, así como, lograr efectos terapéuticos en quienes ya las padecen, sin embargo, aún quedan muchas interrogantes por resolver.
References
Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Molecular Therapy. 2016;24(3):430-46.
Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nature biotechnology. 2016;34(9):933.
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012:1225829.
Dahdouh EM, Balayla J, Audibert F, Wilson RD, Brock J-A, Campagnolo C, et al. Technical update: preimplantation genetic diagnosis and screening. Journal of Obstetrics and Gynaecology Canada. 2015;37(5):451-63.
Krishan K, Kanchan T, Singh B. Human genome editing and ethical considerations. Science and engineering ethics. 2016;22(2):597-9.
The L. Genome editing: science, ethics, and public engagement. Lancet (London, England). 2017;390(10095):625.
Kohn DB, Porteus MH, Scharenberg AM. Ethical and regulatory aspects of genome editing. Blood. 2016:blood-2016-01-678136.
Gaskell G, Bard I, Allansdottir A, Da Cunha RV, Eduard P, Hampel J, et al. Public views on gene editing and its uses. Nature biotechnology. 2017;35(11):1021.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Jorge A. Sánchez-Duque, Andrés M. Patiño-Barbosa, Maria A. Torres-Campo, Maria C. Erazo-Muñoz